Overview

• In mouse models, three injections reduced brain amyloid‑β by roughly 50–60% within one hour, according to the study team.
• The nanoparticles act as supramolecular drugs that engage the LRP1 receptor to reactivate transcytosis and route toxic proteins from brain to bloodstream.
• Treated animals showed improved cognition and behavior with benefits persisting for up to six months in tests of memory and daily activities.
• Researchers report the approach also repaired blood‑brain barrier structure and function, adding transport capacity and restoring vascular health.
• The work, led by teams at UCL, IBEC and West China Hospital, was published in Signal Transduction and Targeted Therapy, and requires replication and safety studies before any human trials.